Conferences

  • Deprez-Poulain, R. First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation,XXVII EFMC International Symposium on Medicinal Chemistry,Nice, France,4-8th september 2022.
  • Deprez-Poulain, R. IDE and ERAP inhibitors discovered by KTGS and their use in therapeutics,GP2A 2022 - 30th Annual Conference,Dublin, IE,24th-26th Aug. 2022 Invited.
  • Deprez-Poulain, R. Kinetic target-guided synthesis et acides hydroxamiques des outils efficaces pour la drug-discovery ciblant les metalloproteases.,CEISAM, Nantes, France,26th Mar. 2021 Invited.
  • Deprez-Poulain, R. Kinetic Target-Guided Synthesis as a Tool for Drug-Discovery: Successes, Challenges and Applications to Metalloproteases,2nd Molecules Medicinal Chemistry Symposium,Barcelona, Spain,15th-17th May 2019 Invited.
  • Deprez-Poulain, R. Validating new metalloproteases targets in drug discovery using small molecules,GDCh-Wissenschaftsforum Chemie,GDCh,Aachen, Germany,15th-18th Sept. 2019 Invited.
  • Deprez-Poulain, R. Pharmacological modulation of antigen processing and presentation: new therapeutic approach for cancer and autoimmune diseases,4th Scientific Meeting of the Institut Pasteur de Lille,Marcq en Baroeul, France,18 Jun. 2018 Invited.
  • Deprez-Poulain, R. Nouveaux médicaments du cancer et des maladies auto-immunes : dompter le système immunitaire à des fins thérapeutiques, Conférences 5 à 7 Médicaments, Institut Pasteur de Lille, France,17th Apr. 2018
  • Deprez-Poulain, R. Validation of Therapeutic targets: utility of hydroxamic acids for the study of metalloproteases like Insulin Degrading Enzyme,2nd Scientific Meeting of the Institut Pasteur de Lille,Marcq en Baroeul,20th Oct 2016
  • Deprez-Poulain, R. From In situ Click to in vivo pharmacology: Effect of catalytic site inhibition of Insulin Degrading Enzyme on glucose tolerance,51st International Conference on Medicinal Chemistry,Avignon, France,1st-3rd July 2015.
  • Deprez-Poulain, R. Zinc-targeting libraries: hits, leads and candidates, GSK, Centre de Recherche François Hyafil, Les Ulis, France,5th May 2015
  • Deprez-Poulain, R. Hydroxamates as tools for the target validation of metalloproteases: Applications to malarial PfAM1 and human Insulin-Degrading Enzyme, National Centre for Scientific Research" Demokritos", Athens, Greece,30th October 2013
  • Deprez-Poulain, R. Inhibiteurs d'aggrecanase (ADAMTS-5) pour le traitement de l’arthrose.,3eme Forum Recherche, School of Pharmacy,Lille, France,6th-7th March 2012
  • Deprez-Poulain, R. Modulation of Metalloenzymes: The Case of Insulin-Degrading Enzyme.,Sanofi-Aventis,Chilly-Mazarin, France,25th Jun. 2011
  • Deprez-Poulain, R. First substrate-dependant modulators of insulin degrading enzyme, Journée Commune SFC/SCT/ANP, Paris,23rd Mar 2010
  • Deprez-Poulain, R. Relever le défi de l'ADME: Etude de cas d'un inhibiteur de la metalloprotease PfAM1 comme antimalarique.,23èmes journées franco-belges de pharmacochimie Mons, Belgium May 29 2009
  • Deprez-Poulain, R. Quelques outils de la chémogénomique : Application à la découverte d’une nouvelle cible antipaludique Pasteur Institute,Journée Petits Déjeuners DrugDiscovery,Lille, France,19 Oct. 2004
  • Poulain, R. Pharmacologie in-vitro et synthèse automatisées : découverte et optimisation rapide de ligands du récepteur aux opiacés de type µ.Journée des Jeunes Chercheurs French Society of Medicinal Chemistry,Paris, France,15 Jan. 1999

PDB structures

5J6S, 4IFH; 4DTT, 2YPU, 4GSC, 4DWK, 4DTV, 4NXO, 4IFH, 4RE9, 7NSK, 7NUP, 7SH0